| Industry | Cons. Staples |
| :--- | :--- | ---: |
| GCPL IN |  |$\quad$.


| Rating Change | $\longleftrightarrow$ |  |  |  |
| :--- | ---: | :---: | :---: | :---: |
| Estimate Change |  |  |  |  |
| Target Change |  |  |  |  |


| Stock Info |  |
| :--- | ---: |
| 52wk Range H/L | $772 / 425$ |
| Mkt Capital (Rs Cr) | 70781 |
| Free float (\%) | $37 \%$ |
| Avg. Vol 1M (,000) | 51 |
| No. of Shares (Cr) | 102 |
| Promoters Pledged \% | NA |

## 1QFY21 Result update

- GODREJCP's 1QFY21 result remained better than our estimates. Sales de-grew by $1 \%$ YoY to Rs. 2327 cr. (vs. our expectation of Rs. 2296 cr.) impacted on account of weak performance from Africa, USA and MENA business due to outbreak of COVID19.
- Domestic volume grew by $3 \%$ YoY driven by strong growth of $27 \% / 15 \%$ YoY from Home Insecticides and Hygiene business led by consumer divergence towards hygiene and safety while Soap and Hair colour business declined by $2 \% / 18 \%$ YoY due to lockdown in the early part of quarter and lower discretionary spends by the consumers.
- On International business front, Indonesia business grew by 5\% in cc terms led by Household Insecticides while the company's Africa, USA and Middle East business remained impacted due to COVID-19 led disruption and de-grew by $23 \%$ in cc terms.

G Gross margin deteriorated by 286 bps YoY to 54.3\% YoY impacted due to adverse category mic and higher input prices while EBITDA margin improved by 91 bps YoY to $20.3 \%$ led by decline in Ad \& $P$ expense.

- PAT for this quarter de-grew by $3.1 \%$ YoY to Rs. 395 cr. (vs. expectation of Rs. 330 cr.) while PAT margin declined by 39 bps YoY to $17 \%$.


## View and Valuation

GODREJCP has reported numbers better than our expectations. New and differentiated launches in the Hygiene and Home Insecticides category coupled with focus on distribution and micro marketing initiatives led to domestic volume growth of $3 \% \mathrm{YoY}$ during the quarter despite prevailing macroeconomic challenges. On the International business front, growth was supported by Indonesia business which grew by $5 \%$ in cc terms. Going forward, we expect company's Home Insecticides and Hygiene portfolio to perform better led by monsoon and consumer divergence towards hygiene and safety while Soaps are expected to recover slowly on the back of micro marketing initiatives while on International business front we expect growth trajectory to continue in Indonesia business while Africa business is expected to turn around on the back of appointment of new management. However, macros prevailing in domestic as well as International markets remains the concern. The Company will be judicious on A\&P expenses considering sluggish macro condition; hence we have reduced our Ad expense but maintain our HOLD rating with a target price of Rs. 768 .

## Key Risks to our rating and target

Sharp improvement in Africa, Middele East and USA business.
$\square$ Steep increase in input prices
Fig in Rs Cr

| KEY FINANCIAL/VALUATIONS | FY17 | FY18 | FY19 | FY20 | FY21E |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Net Sales | 9268 | 9843 | 10314 | 9911 | 10543 |
| EBITDA | 1898 | 2067 | 2118 | 2143 | 2483 |
| EBIT | 1756 | 1911 | 1948 | 1946 | 2283 |
| PAT | 1307 | 1633 | 2341 | 1496 | 1795 |
| EPS (Rs) | 38 | 24 | 23 | 15 | 18 |
| EPS growth (\%) | $58 \%$ | $-38 \%$ | $-5 \%$ | $-36 \%$ | $20 \%$ |
| ROE (\%) | $25 \%$ | $26 \%$ | $32 \%$ | $19 \%$ | $21 \%$ |
| ROCE (\%) | $21 \%$ | $22 \%$ | $20 \%$ | $19 \%$ | $22 \%$ |
| BV | 156 | 92 | 71 | 77 | 85 |
| P/B (X) | 11 | 12 | 9 | 9 | 8 |
| $P / E(x)$ | 43 | 48 | 32 | 44 | 40 |

## 1QFY21 Results

## Better than expectation

| Fin | 10 | 20 | 3 | 4Q | 101 |  |  |  | Fig in Rs Cr |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 2,349 | 2,630 | 2,778 | 2,154 | 2,327 | -0.9\% | 8.1\% | 10,221 | 9,827 | -3.9\% |
| Other Income | 21 | 27 | 24 | 49 | 22 | 2\% | -55.7\% | 109 | 112 | 3.3\% |
| COGS | 1,007 | 1,142 | 1,202 | 911 | 1,064 | 5.7\% | 16.9\% | 4,554 | 4,262 | -6.4\% |
| Gross Margin | 57\% | 57\% | 57\% | 58\% | 54\% | -2.9\% | -3.5\% | 56\% | 57\% | 1.2\% |
| Empl. Cost | 265 | 267 | 269 | 224 | 262 | -1.3\% | 17.0\% | 1,091 | 1,019 | -6.6\% |
| A\&P expenses | 193 | 213 | 206 | 127 | 105 | -45.7\% | -17.3\% | - | - | - |
| Other Exp. | 425 | 432 | 469 | 416 | 424 | -0.2\% | 1.7\% | 2,552 | 2,487 | -2.5\% |
| EBITDA | 456 | 572 | 631 | 477 | 473 | 3.8\% | -0.8\% | 2,118 | 2,143 | 1.2\% |
| EBITDA Mar. | 19\% | 22\% | 23\% | 22\% | 20\% | 0.9\% | -1.8\% | 21\% | 22\% | 1.1\% |
| Depreciation | 47 | 48 | 49 | 53 | 49 | 4.2\% | -7.2\% | 170 | 197 | 16.1\% |
| EBIT | 408 | 524 | 582 | 423 | 423 | 3.7\% | 0.0\% | 1,948 | 1,946 | -0.1\% |
| Interest | 55 | 53 | 48 | 62 | 48 | -12\% | -21\% | 224 | 217 | -3.1\% |
| PBT | 375 | 498 | 557 | 411 | 397 | 5.9\% | -3.5\% | 1,832 | 1,841 | 0\% |
| Exceptional | (0) | 4 | 4 | 73 | (13) | 4607.1\% | -117.9\% | 253 | (81) | -132\% |
| Tax | (33) | 80 | 108 | 107 | 15 | -145.2\% | -86.3\% | (256) | 264 | -203\% |
| PAT | 408 | 414 | 445 | 230 | 395 | -3.1\% | 71.8\% | 2,341 | 1,496 | -36\% |
| PAT Margin | 17\% | 16\% | 16\% | 11\% | 17\% | -0.4\% | 6.3\% | 23\% | 15\% | -7.6\% |

## Concall Highlights

$>$ For the Company rural grew ahead of urban and the management expects the trajectory to continue led by the company's strong distribution and product portfolio.
> The Company witnessed sequential improvement in business in Africa, USA and Middle East in the months of May, June and July.
> With the change in management for Africa the company remains confident of positive performance from the Africa business.
> The Company's working capital days came down by 6 days while debt to equity ratio came down to 0.17 times in 1QFY21.
> The illegal incense stick market remained impacted due to supply chain disruption amidst COVID-19 and increase in duty of bamboo sticks which has been imported from China and Vietnam has increased from $10 \%$ to $25 \%$ in 1QFY21.
$>$ The Company witnessed strong growth of $15 \%$ in Hygiene. The Company launched 45 products across geographies and will continue to focus on the category in coming quarters.
> Gross margin in domestic business declined by 300 bps on account of adverse category mix and higher input prices.
> The Company witnessed strong growth in burning and electric formats while Aerosol remained impacted due to supply chain disturbance in the HI category in 1QFY21.
$>$ The Management expects sequential increase in Ad \& P led by demand conditions in coming quarters.
> The Management expects gross margin to improve led by favorable category mix and pricing action in 2QFY21.
> The Company will continue investing in Godrej Protekt soap and will also continue micro marketing initiative in the portfolio which has helped the company in gaining market share.
> The Management does not expect any meaningful CAPEX for India and Indonesia business in the rest of the year.
> The Management expects stable performance from the Home Insecticide category for the rest of the year from both India and International markets and will also come up with new launches in the category.
> The Management expects the skin cleansing category to grow in coming months.

## GODREJCP

## Exhibit: Domestic Soap Business growth

Domestic Soap business remained impacted due to nationwide lockdown in the first month of quarter amidst COVID-19.


Exhibit: Domestic Hair colour Business growth
Hair colour business remained impacted on account of nationwide lockdown in April.
$\longrightarrow$ Domestic Hair colour Revenue growth YoY


Exhibit: Sales and Sales Growth
Sales remained impacted on account of weak performance from Africa, USA and Middle East business amidst COVID-19.


Exhibit: Domestic HI Business growth
Strong double digit growth led by consumer focus towards disease prevention amidst COVID-19.


## Exhibit: Indonesia Market CC Growth

Indonesia business growth was led by improvement in Household Insecticide business with market share gain.
——Indonesian Market CC growth YoY


Exhibit: Gross margin and EBITDA margin
Gross margin declined on account of adverse category mix and higher input prices in 1QFY21.


## GODREJCP

Financial Details
Balance Sheet
Fig in Rs Cr

| Y/E March | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21E |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Share Capital | 34 | 34 | 34 | 34 | 68 | 102 | 102 | 102 |
| Reserves | 3,741 | 4,277 | 4,233 | 5,268 | 6,190 | 7,165 | 7,796 | 8,606 |
| Networth | 3,775 | 4,311 | 4,267 | 5,302 | 6,258 | 7,267 | 7,898 | 8,708 |
| Debt | 1,702 | 2,170 | 2,631 | 3,341 | 2,521 | 2,876 | 2,664 | 2,064 |
| Other Non Current Liab | 34 | 34 | 313 | 1,238 | 1,159 | 407 | 367 | 367 |
| Total Capital Employed | 5,477 | 6,480 | 6,898 | 8,643 | 8,779 | 10,143 | 10,562 | 10,772 |
| Net Fixed Assets (incl CWIP) | 1,736 | 1,732 | 1,831 | 3,524 | 3,680 | 3,804 | 3,949 | 3,973 |
| Non Current Investments | 34 | 34 | - | - | - | - | - | - |
| Other Non Current Assets | 3,736 | 4,287 | 4,339 | 4,969 | 4,884 | 5,521 | 6,031 | 6,031 |
| Non Current Assets | 5,506 | 6,052 | 6,259 | 8,814 | 8,795 | 9,482 | 10,149 | 10,172 |
| Inventory | 1,082 | 1,072 | 1,307 | 1,413 | 1,578 | 1,559 | 1,703 | 1,812 |
| Debtors | 711 | 805 | 1,118 | 1,029 | 1,246 | 1,293 | 1,157 | 1,231 |
| Cash \& Bank | 705 | 894 | 613 | 895 | 898 | 862 | 603 | 1,151 |
| Other Current Assets | 320 | 319 | 305 | 830 | 1,182 | 784 | 1,010 | 878 |
| Current Assets | 2,818 | 3,090 | 3,494 | 4,217 | 5,168 | 4,688 | 4,808 | 5,250 |
| Creditors | 1,234 | 1,087 | 1,485 | 1,724 | 2,357 | 2,540 | 2,480 | 2,639 |
| Provisions | 56 | 98 | 70 | 90 | 48 | 51 | 56 | 60 |
| Other Current Liabilities | 1,298 | 1,281 | 315 | 307 | 311 | 167 | 85 | 90 |
| Curr Liabilities | 2,588 | 2,466 | 2,533 | 3,150 | 4,024 | 3,621 | 4,028 | 4,283 |
| Net Current Assets | 230 | 624 | 962 | 1,067 | 1,143 | 1,068 | 780 | 967 |
| Total Assets | 8,325 | 9,142 | 9,754 | 13,031 | 13,963 | 14,170 | 14,957 | 15,422 |

Income Statement
Fig in Rs Cr

| Y/E March | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21E |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue from Operation | $\mathbf{7 , 6 0 2}$ | $\mathbf{8 , 2 7 6}$ | $\mathbf{8 , 4 2 4}$ | $\mathbf{9 , 2 6 8}$ | $\mathbf{9 , 8 4 3}$ | $\mathbf{1 0 , 3 1 4}$ | $\mathbf{9 , 9 1 1}$ | $\mathbf{1 0 , 5 4 3}$ |
| Change (\%) | $18 \%$ | $9 \%$ | $2 \%$ | $10 \%$ | $6 \%$ | $5 \%$ | $-4 \%$ | $6 \%$ |
|  |  |  |  |  |  |  |  |  |
| EBITDA | $\mathbf{1 , 1 5 0}$ | $\mathbf{1 , 3 6 5}$ | $\mathbf{1 , 6 3 6}$ | $\mathbf{1 , 8 9 8}$ | $\mathbf{2 , 0 6 7}$ | $\mathbf{2 , 1 1 8}$ | $\mathbf{2 , 1 4 3}$ | $\mathbf{2 , 4 8 3}$ |
| Change (\%) | $17 \%$ | $19 \%$ | $20 \%$ | $16 \%$ | $9 \%$ | $2 \%$ | $1 \%$ | $16 \%$ |
| Margin (\%) | $15 \%$ | $16 \%$ | $19 \%$ | $20 \%$ | $21 \%$ | $21 \%$ | $22 \%$ | $\mathbf{2 4 \%}$ |
| Depr \& Amor. | 82 | 91 | 101 | 142 | 156 | 170 | 197 | 200 |
| EBIT | $\mathbf{1 , 0 6 8}$ | $\mathbf{1 , 2 7 5}$ | $\mathbf{1 , 5 3 5}$ | $\mathbf{1 , 7 5 6}$ | $\mathbf{1 , 9 1 1}$ | $\mathbf{1 , 9 4 8}$ | $\mathbf{1 , 9 4 6}$ | $\mathbf{2 , 2 8 3}$ |
| Int. \& other fin. Cost | 107 | 100 | 119 | 145 | 161 | 224 | 217 | 199 |
| Other Income | 63 | 92 | 84 | 75 | 108 | 109 | 112 | 127 |
| EBT | $\mathbf{1 , 0 2 4}$ | $\mathbf{1 , 2 6 6}$ | $\mathbf{1 , 5 0 0}$ | $\mathbf{1 , 6 8 6}$ | $\mathbf{1 , 8 5 8}$ | $\mathbf{1 , 8 3 2}$ | $\mathbf{1 , 8 4 1}$ | $\mathbf{2 , 2 1 1}$ |
| Exp Item | 6 | $117)$ | $(334)$ | 0 | 180 | 253 | $(81)$ | 13 |
| Tax | 210 | 272 | 336 | 379 | 405 | $(256)$ | 264 | 430 |
| Minority Int \& P/L share of Ass. | 60 | 69 | 3 | 1 | 1 | - | 1 | 1 |
| Reported PAT | 760 | 907 | 828 | 1,308 | 1,634 | 2,341 | 1,497 | 1,796 |
| Adjusted PAT | $\mathbf{7 5 5}$ | $\mathbf{9 2 1}$ | $\mathbf{1 , 0 8 6}$ | $\mathbf{1 , 3 0 8}$ | $\mathbf{1 , 4 9 4}$ | $\mathbf{2 , 0 5 3}$ | $\mathbf{1 , 5 6 6}$ | $\mathbf{1 , 7 8 5}$ |
| Change (\%) | $9 \%$ | $22 \%$ | $18 \%$ | $20 \%$ | $14 \%$ | $37 \%$ | $-24 \%$ | $14 \%$ |
| Margin(\%) | $10 \%$ | $11 \%$ | $13 \%$ | $14 \%$ | $15 \%$ | $20 \%$ | $16 \%$ | $17 \%$ |

## GODREJCP

Financial Details
Key Ratios

| Y/E March | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21E |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| ROE | $20 \%$ | $21 \%$ | $19 \%$ | $25 \%$ | $26 \%$ | $32 \%$ | $19 \%$ | $21 \%$ |
| ROCE | $20 \%$ | $20 \%$ | $23 \%$ | $21 \%$ | $22 \%$ | $20 \%$ | $19 \%$ | $22 \%$ |
| Asset Turnover | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Debtor Days | 34 | 35 | 48 | 41 | 46 | 46 | 43 | 43 |
| Inv Days | 52 | 47 | 57 | 56 | 59 | 55 | 63 | 63 |
| Payable Days | 59 | 48 | 64 | 68 | 87 | 90 | 91 | 91 |
| Int Coverage | 10 | 13 | 13 | 12 | 12 | 9 | 9 | 11 |
| P/E | 38 | 30 | 46 | 43 | 48 | 32 | 44 | 40 |
| Price / Book Value | 8 | 6 | 12 | 11 | 12 | 9 | 9 | 8 |
| EV/EBITDA | 26 | 21 | 31 | 31 | 36 | 32 | 33 | 29 |
| FCF per Share | 10 | 8 | 6 | 16 | 14 | 15 | 14 | 20 |
| Div Yield | $1 \%$ | $1 \%$ | $1 \%$ | $1 \%$ | $1 \%$ | $2 \%$ | $1 \%$ | $1 \%$ |

Cash Flow Statement
Fig in Rs Cr

| Y/E March | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PBT | 1,024 | 1,266 | 1,500 | 1,687 | 1,859 | 1,833 | 1,841 | 2,225 |
| (inc)/Dec in Working Capital | 199 | (113) | (486) | 301 | (16) | 1 | (261) | 39 |
| Non Cash Op Exp | 59 | 63 | 116 | 140 | 196 | 199 | 211 | 200 |
| Int Paid (+) | 107 | 100 | 119 | 145 | 161 | 224 | 217 | 199 |
| Tax Paid | (238) | (257) | (336) | (407) | (393) | (435) | (344) | (430) |
| others | (23) | (54) | (66) | (61) | (84) | (105) | (89) | - |
| CF from Op. Activities | 1,129 | 1,005 | 847 | 1,805 | 1,723 | 1,729 | 1,588 | 2,233 |
| (inc)/Dec in FA \& CWIP | (133) | (190) | (208) | (180) | (311) | (208) | (152) | (223) |
| Free Cashflow | 996 | 814 | 639 | 1,625 | 1,412 | 1,521 | 1,436 | 2,010 |
| (Pur)/Sale of Inv | 74 | (450) | 210 | (393) | 214 | 329 | (512) | 156 |
| others | (436) | (574) | (605) | $(1,597)$ | (146) | 178 | 306 | - |
| CF from Inv. Activities | (495) | $(1,214)$ | (602) | $(2,170)$ | (340) | 252 | (533) | (67) |
| inc/(dec) in NW | 0 | - | 0 | 0 | 0 | 0 | 0 | (0) |
| inc/(dec) in Debt | (321) | 300 | 142 | 1,024 | (488) | (345) | - | (600) |
| Int. Paid | (113) | (119) | (119) | (124) | (158) | (215) | (152) | (199) |
| Div Paid (inc tax) | (170) | (179) | (187) | (196) | (613) | $(1,227)$ | (818) | (986) |
| others | (29) | (14) | (38) | (40) | (125) | (252) | (168) | - |
| CF from Fin. Activities | (633) | (12) | (202) | 665 | $(1,384)$ | $(2,039)$ | $(1,295)$ | $(1,785)$ |
| Inc(Dec) in Cash | 1 | (221) | 43 | 300 | (0) | (58) | (240) | 381 |
| Add: Opening Balance | 624 | 625 | 570 | 595 | 898 | 895 | 855 | 770 |
| Closing Balance | 625 | 404 | 613 | 895 | 898 | 862 | 603 | 1,151 |

 have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.
 or completeness guaranteed.
 Broking, Depository Participant, Merchant Banking, Portfolio Management \& distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com














 the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.
 analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

## Disclosure of Interest Statement-

Analyst's ownership of the stocks mentioned in the Report NIL

## A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com

Correspondence Office Address: Arch Waterfront, $5^{\text {th }}$ Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.
Registered Office Address: Marble Arch, Office 201, $2^{\text {nd }}$ Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com
Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.
 Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087


 Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:B.05.02568.

## Disclaimer:














 employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.
 law, regulation or which would subject NFAL \& its group companies to registration or licensing requirements within such jurisdictions.

